Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|October 15, 2026

The BioPharm Brief: New Approvals, Biosimilar Competition, and Deeper Remission

FDA expands Anktiva’s bladder cancer indication, Alvotech and Advanz submit a proposed Eylea 8 mg biosimilar in Europe, and Lilly reports new remission data for Omvoh in inflammatory bowel disease.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we’re looking at an expanded cancer treatment approval, a new biosimilar regulatory milestone, and clinical data raising the bar for remission in inflammatory bowel disease.

First, the FDA has expanded approval of ImmunityBio’s Anktiva plus BCG, to include patients with BCG-unresponsive non-muscle invasive bladder cancer whose tumors are papillary-only. The agency extended the existing indication by extrapolating efficacy data from patients with carcinoma in situ, rather than requiring separate efficacy results in the papillary-only population. The decision came nearly three months before the FDA’s target action date and broadens treatment options for patients who have not responded to BCG.

Next, Alvotech and Advanz Pharma have submitted AVT29, a proposed biosimilar to high-dose aflibercept, or Eylea 8 mg, to the European Medicines Agency. The companies say this is the first known regulatory submission worldwide for a biosimilar to the 8 mg formulation. That dose can allow treatment intervals of up to 16 weeks for certain patients, compared with eight weeks for the 2 mg formulation. The application builds on the companies’ existing European authorization for their aflibercept 2 mg biosimilar, Mynzepli. AVT29 remains investigational, and biosimilarity has not yet been established by regulators.

Finally, Eli Lilly has reported new analyses of mirikizumab, marketed as Omvoh, in ulcerative colitis and Crohn disease. At one year, 27.7% of patients with ulcerative colitis achieved comprehensive disease control, compared with 14% receiving placebo. In Crohn disease, 20.4% of patients achieved corticosteroid-free deep remission, compared with 2% receiving placebo. The analyses also found benefits among patients who had previously failed biologic treatment. These were post hoc analyses of existing Phase 3 trial data, not new primary endpoints or a new regulatory approval.

For more biopharmaceutical news and analysis, visit BioPharmInternational.com.Thanks for listening!

Key takeaways

  • Anktiva: FDA expands its bladder cancer indication to include papillary-only disease.
  • AVT29: Alvotech and Advanz submit a proposed Eylea 8 mg biosimilar in Europe.
  • Omvoh: Lilly reports new composite remission outcomes in ulcerative colitis and Crohn disease.

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.